Abeona Therapeutics Inc
ABEO5.440USD
+0.330+6.46%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
285.06MMarket Cap
3.36P/E TTM
More Details of Abeona Therapeutics Inc Company
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).
Abeona Therapeutics Inc Info
Ticker SymbolABEO
Company nameAbeona Therapeutics Inc
IPO dateSep 19, 1980
CEOSeshadri (Vishwas)
Number of employees136
Security typeOrdinary Share
Fiscal year-endSep 19
Address6555 Carnegie Ave, 4th Floor
CityCLEVELAND
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code44103
Phone16468134701
Websitehttps://abeonatherapeutics.com/
Ticker SymbolABEO
IPO dateSep 19, 1980
CEOSeshadri (Vishwas)
Company Executives of Abeona Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Vishwas (Vish) Seshadri, Ph.D.
Dr. Vishwas (Vish) Seshadri, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.19M
-0.02%
Mr. Michael Amoroso
Mr. Michael Amoroso
Chairman of the Board
Chairman of the Board
180.47K
--
Dr. Leila Alland, M.D.
Dr. Leila Alland, M.D.
Independent Director
Independent Director
154.37K
--
Mr. Donald A. Wuchterl
Mr. Donald A. Wuchterl
Independent Director
Independent Director
145.44K
-3.44%
Ms. Christine Berni Silverstein
Ms. Christine Berni Silverstein
Independent Director
Independent Director
120.48K
-9.80%
Mr. Mark J. Alvino
Mr. Mark J. Alvino
Independent Director
Independent Director
62.34K
-19.39%
Dr. Bernhardt G. Zeiher, M.D.
Dr. Bernhardt G. Zeiher, M.D.
Independent Director
Independent Director
47.15K
--
Dr. Eric Crombez, M.D.
Dr. Eric Crombez, M.D.
Independent Director
Independent Director
--
--
Mr. Joseph Vazzano, CPA
Mr. Joseph Vazzano, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Faith L. Charles, J.D.
Ms. Faith L. Charles, J.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Vishwas (Vish) Seshadri, Ph.D.
Dr. Vishwas (Vish) Seshadri, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.19M
-0.02%
Mr. Michael Amoroso
Mr. Michael Amoroso
Chairman of the Board
Chairman of the Board
180.47K
--
Dr. Leila Alland, M.D.
Dr. Leila Alland, M.D.
Independent Director
Independent Director
154.37K
--
Mr. Donald A. Wuchterl
Mr. Donald A. Wuchterl
Independent Director
Independent Director
145.44K
-3.44%
Ms. Christine Berni Silverstein
Ms. Christine Berni Silverstein
Independent Director
Independent Director
120.48K
-9.80%
Mr. Mark J. Alvino
Mr. Mark J. Alvino
Independent Director
Independent Director
62.34K
-19.39%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Nantahala Capital Management, LLC
8.42%
Adage Capital Management, L.P.
5.62%
BlackRock Institutional Trust Company, N.A.
5.26%
James Russell Revocable Trust
5.02%
Suvretta Capital Management, LLC
4.94%
Other
70.74%
Shareholders
Shareholders
Proportion
Nantahala Capital Management, LLC
8.42%
Adage Capital Management, L.P.
5.62%
BlackRock Institutional Trust Company, N.A.
5.26%
James Russell Revocable Trust
5.02%
Suvretta Capital Management, LLC
4.94%
Other
70.74%
Shareholder Types
Shareholders
Proportion
Hedge Fund
29.19%
Investment Advisor
18.72%
Investment Advisor/Hedge Fund
9.68%
Individual Investor
5.33%
Corporation
5.02%
Research Firm
4.84%
Venture Capital
4.23%
Bank and Trust
0.09%
Pension Fund
0.06%
Other
22.85%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
204
36.22M
79.02%
-9.77K
2025Q3
209
38.81M
82.28%
+643.18K
2025Q2
192
38.19M
68.92%
+5.47M
2025Q1
135
32.70M
74.05%
-3.55M
2024Q4
131
33.67M
75.84%
+1.89M
2024Q3
124
31.78M
82.54%
-3.17M
2024Q2
126
34.94M
52.06%
+14.17M
2024Q1
122
17.08M
56.78%
+1.44M
2023Q4
112
16.39M
53.86%
+3.77M
2023Q3
118
12.21M
54.85%
+1.48M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Nantahala Capital Management, LLC
4.56M
8.9%
+195.00K
+4.46%
Sep 30, 2025
Adage Capital Management, L.P.
3.07M
5.99%
+381.36K
+14.17%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.72M
5.3%
+2.24M
+475.57%
Jun 30, 2025
Suvretta Capital Management, LLC
2.68M
5.22%
-1.01M
-27.39%
Jun 30, 2025
The Vanguard Group, Inc.
2.51M
4.89%
+486.84K
+24.10%
Jun 30, 2025
Vivo Capital, LLC
1.84M
3.59%
--
--
Jun 30, 2025
Western Standard, LLC
2.09M
4.08%
-189.60K
-8.31%
Jun 30, 2025
Seshadri (Vishwas)
1.19M
2.32%
-44.27K
-3.59%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Simplify Propel Opportunities ETF
3.97%
iShares Micro-Cap ETF
0.04%
Proshares Ultra Russell 2000
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Growth ETF
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
Vanguard US Momentum Factor ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
View more
Simplify Propel Opportunities ETF
Proportion3.97%
iShares Micro-Cap ETF
Proportion0.04%
Proshares Ultra Russell 2000
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
iShares Russell 2000 Growth ETF
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
Vanguard US Momentum Factor ETF
Proportion0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jul 01, 2022
Merger
25→1
Jul 01, 2022
Merger
25→1
Jul 01, 2022
Merger
25→1
Jul 01, 2022
Merger
25→1
Date
Type
Ratio
Jul 01, 2022
Merger
25→1
Jul 01, 2022
Merger
25→1
Jul 01, 2022
Merger
25→1
Jul 01, 2022
Merger
25→1
FAQs
Who are the top five shareholders of Abeona Therapeutics Inc?
The top five shareholders of Abeona Therapeutics Inc are:
Nantahala Capital Management, LLC holds 4.56M shares, accounting for 8.90% of the total shares.
Adage Capital Management, L.P. holds 3.07M shares, accounting for 5.99% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.72M shares, accounting for 5.30% of the total shares.
Suvretta Capital Management, LLC holds 2.68M shares, accounting for 5.22% of the total shares.
The Vanguard Group, Inc. holds 2.51M shares, accounting for 4.89% of the total shares.
Nantahala Capital Management, LLC holds 4.56M shares, accounting for 8.90% of the total shares.
Adage Capital Management, L.P. holds 3.07M shares, accounting for 5.99% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.72M shares, accounting for 5.30% of the total shares.
Suvretta Capital Management, LLC holds 2.68M shares, accounting for 5.22% of the total shares.
The Vanguard Group, Inc. holds 2.51M shares, accounting for 4.89% of the total shares.
What are the top three shareholder types of Abeona Therapeutics Inc?
The top three shareholder types of Abeona Therapeutics Inc are:
Nantahala Capital Management, LLC
Adage Capital Management, L.P.
BlackRock Institutional Trust Company, N.A.
Nantahala Capital Management, LLC
Adage Capital Management, L.P.
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of Abeona Therapeutics Inc (ABEO)?
As of 2025Q4, 204 institutions hold shares of Abeona Therapeutics Inc, with a combined market value of approximately 36.22M, accounting for 79.02% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -3.26%.
What is the biggest source of revenue for Abeona Therapeutics Inc?
In --, the -- business generated the highest revenue for Abeona Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
